Fractyl Health GUTS 深 滬
等待開盤 09-24 09:30:00 美东时间
0.4856
-0.067
-12.19%
華盛通- 最 高0.5587
- 今 開0.5516
- 成交量 472.65万股
- 最 低 0.4556
- 昨 收 0.553
- 總市值 7729.77万
- 52周最高 2.445
- 市盈率 靜 --
- 換手率 2.97%
- 52周最低 0.3772
- 委 比 -84.62%
- 總股本 1.59亿
- 歷史最高 14.50
- 量 比 4.51
- 振 幅 18.64%
- 歷史最低 0.3772
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fractyl Health Faces Nasdaq Delisting, Plans Reverse Split
Fractyl Health, Inc. ( ($GUTS) ) just unveiled an update. On March 13, 2026, Fr...
09-12 04:52
Fractyl Health to Participate in Upcoming September Investor Conferences
Fractyl Health, Inc. announced that its CEO, Harith Rajagopalan, M.D., Ph.D., will participate in two upcoming investor conferences: the H.C. Wainwright 28th Annual Global Investment Conference on September 11 and 15, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. The company, focused on treating obesity and type 2 diabetes, is advancing therapies targeting the root causes of these conditions. Webcast...
09-09 11:00
Fractyl Health Earnings Call Signals Promise Amid Risks
Fractyl Health, Inc. (($GUTS)) has held its Q2 earnings call. Read on for the m...
08-23 08:26
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance
Fractyl Health, Inc. announced it will host a virtual Commercial Strategy Day on September 1, 2026, to discuss the commercial potential and go-to-market strategy for Revita®, a one-time procedural therapy for weight maintenance after GLP-1 therapy discontinuation. The event follows positive one-year data from the REMAIN-1 Midpoint Cohort, showing Revita-treated participants maintained 84% of their GLP-1-induced weight loss compared to 46% in sham...
08-20 11:00
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
Fractyl Health announced second quarter 2026 financial results and updates, highlighting Revita's effectiveness in maintaining weight loss post-GLP-1 discontinuation. One-year data from the REVEAL-1 Cohort showed patients maintained 78% of weight loss after a single Revita procedure. REMAIN-1 Midpoint Cohort data demonstrated Revita-treated patients maintained 84% of weight loss versus 46% in sham. The company reaffirmed its 2026 milestones, incl...
08-10 20:05
Fractyl Health to Participate in Upcoming Investor Events
Fractyl Health, Inc. announced that its CEO, Harith Rajagopalan, will participate in three upcoming investor conferences in July and August 2026. These include the BTIG Virtual Biotechnology Conference (July 28-29), the Needham & Company MedTech & Diagnostics 1x1 Conference (August 10-11), and the Canaccord Genuity 46th Annual Growth Conference (August 12). A live webcast will be available on the company’s website, with an archive for 90 days. Fr...
07-22 20:01
美股牛股 | AI数据中心需求引爆订单！AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购
Lucid劲升近29%！聘请重组顾问扭转经营颓势；AI数据中心需求引爆订单，AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购>>
07-16 19:21
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health Inc. (NASDAQ:GUTS) reported Wednesday one-year results from the Midpoint Cohort of its REMAIN-1 study, saying a single treatment with its investigational Revita DMR System helped patients maintain more of their GLP-1-induced weight loss than a sham procedure. The clinical-stage metabo...
07-16 02:22
Fractyl gains as Revita procedure reduces weight gain in post-GLP-1 setting
Fractyl Health (GUTS) added ~9% in the morning trading on Wednesday after the metabolic therapeutics company said that its Revita procedure reduced weight regain by roughly 40% following GLP-1 discont...
07-15 22:48
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
Fractyl Health announced positive one-year results from its REMAIN-1 Midpoint Cohort, showing that Revita maintained 84% of GLP-1-induced weight loss versus 46% with sham in patients with complete duodenal ablation. The procedure demonstrated excellent tolerability with no serious adverse events. Key findings include dose-dependent durability, greater benefit for high-need patients, and a 91% weight-maintenance responder rate in optimized populat...
07-15 10:00
